Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While Dulaglutide is a once-weekly GLP-1RA for type 2 diabetes that lowers HbA1c and body weight by enhancing glucose-dependent insulin secretion and reducing appetite6668, PEG-MGF is used experimentally to enhance muscle repair and hypertrophy after mechanical overload or injury by stimulating satellite-cell activation and protein synthesis6373138.
While Dulaglutide works as a recombinant fusion protein consisting of two disulfide-linked GLP-1(7–37) analogs each covalently fused via a linker to an IgG4 Fc fragment, yielding a large, long-acting GLP-1 receptor agonist protected from DPP-4 degradation66, PEG-MGF is a poly(ethylene glycol)-conjugated form of Mechano Growth Factor (IGF-1Ec splice variant) comprising the 24-aa C-terminal E-peptide of IGF-1, designed to extend half-life while activating IGF-1 receptor–mediated anabolic signaling in muscle satellite cells637322138.
Dulaglutide
GCG
PEG-MGF
IGF1
Dulaglutide and PEG-MGF are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: Dulaglutide is more often discussed in the realm of Metabolic and endocrine, whereas PEG-MGF is more often associated with the realm of Musculoskeletal health and Cardiovascular health. Their biological logic is quite different: Dulaglutide is a receptor agonist, whereas PEG-MGF is a growth factor mimetic and a signaling modulator. Dulaglutide has a more engineered peptide origin, while PEG-MGF is closer to synthetic analog background and their development context also differs, with Dulaglutide approved while PEG-MGF is in Preclinical development. PEG-MGF incorporates pegylation features that are not part of Dulaglutide, while their sequence patterns also diverge, with Dulaglutide showing alpha-helical domain features and PEG-MGF showing protein-mimetic sequence features.